Breast Cancer Research and Treatment **48**: 289-290, 1998.
© 1998 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 48

A'Hern R 107
Allred DC 11
Andersen TI 259
Apostolikas N 205
Arber N 195
Ashley SE 11,81

Baldwin MA 243
Ballinger JR 73
Benz CC 243
Bergoc R 175
Berns EMJJ 87
Bhachech SH 187
Bhatavdekar JM 187
Blank EW 135
Boorne AJ 117
Børreson-Dale A-L 259
Boyd NF 65
Brazel S 53
Bremmer WJ 45
Brooks KM 231
Bui T 273
Bukholm I 259
Burton SA 107
Butler K 53

Cacciafesta M 159
Cantell K 135
Cardinali A 211
Ceriani RL 135
Chang C-H 243
Chang J 81
Cline JM 221
Cocca C 175
Collett K 1
Cricco G 175

Daidone MG 93
Dalal AA 187
Davio C 175
De Rosa CM 135
De Vincentis G 159
Delohery T 195
Demers LM 45
Detre S 107
Dhingra K 165
Di Mauro MG 93
Diamandis EP 73
Donnelly N 117
Dowsett M 11,81,107
Drach J 125

Ellis PA 107
Emami K 165
Engel N 175
Esplen MJ 53
Estrov Z 165

Feigl M 125
Felgner C 97
Filipits M 125
Foekens JA 87
Fukutomi T 21

Gao J 53
Gazzanelli G 211
Gianni W 159
Goodwin P 53
Gray D 273
Gregory RK 81
Griniatsos J 205

Haensch W 97
Han EK-H 195
Herbert RA 265
Hirohashi S 21
Hohenberger P 97
Hortobagyi G 165
Horwitz KB 231
Huber H 125

Iveson T 81

Jakesz R 125
Johnston SRD 107

Klamut HJ 273
Klijn JGM 87
Knight JA 65
Kogan I 73
Konstantinidou A 205
Kuba RM 73
Kuppinen H-L 135

Lange C 231
Li P 273
Liang X 243
Libstug AR 65
Lim JTE 195
Lu B 243
Luisi A 93

Mæhle BO 1
Makris A 11
Malatesta M 211
Mannello F 211
Marcheggiani F 211
Marigliano V 159
Martin G 175
Melegos DN 73
Miller A 53
Moravan V 65

Ney E 265
Nohara K 149

Ormerod MG 11
Ozzello L 135

Pamukcu R 195
Pani R 159
Patel DD 187
Patel RR 187
Pellegrini R 159
Piazza GA 195
Powles TJ 11,81
Pritchard K 53

Rao GN 265

Rauth AM 73
Redshaw R 73
Renò F 211
Richer JK 231
Rivera E 175
Roka S 125
Roy SK 187

Sahin A 165
Sakamaki C 21
Salter J 107
Santen RJ 45
Santner SJ 45
Schlag PM 97
Schrey MP 117
Schuster R 125
Scopinaro F 159
Scott GK 243
Sebastiani M 211
Silvestrini R 93
Sinha S 45
Skjærven R 1
Skoog L 221
Smith IE 107
Soderqvist G 221
Soluri A 159
Sørlie T 259
Spiegel S 149
Steiner B 125

Takimoto GS 231
Thomas T 243
Titley JC 11
Tölö H 135
Trivedi AH 187
Troisi G 159
Tsuda H 21
Tsugane S 21
Tung L 231
van Staveren IL 87
Vassilopoulos 205
Voigt JM 33
von Schoultz E 221
von Schoultz B 221

Walsh G 107
Wang F 149
Weinstein IB 195
Wierman AM 231
Winocur J 53

Xing WQ 195

Yamamoto H 195
Yang X 33
Young LH 33

Zissis Ch 205
Zojer N 125

Breast Cancer Research and Treatment **48**: 291–294, 1998.
© 1998 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 48

4-hydroxyphenyl retinamide (4-HPR)
inhibition of mammary tumor development in *neu* transgenic mice 265-271

adenoviral vectors
apoptosis in MCF-7 cells after infection with p53-carrying adenovirus 273-286
apocrine cells
gross cystic breast disease — classification and hypothetical evolution 211-219
apoptosis
decreased in residual breast cancer following preoperative chemotherapy 107-116
induction by sulindac and metabolites in breast and breast cancer cells 195-203
aromatase inhibitors
letrozole, unlike aminoglutethimide, inhibits ovarian as well as tumor aromatase 45-51
arotinoid Ro 40-8757
inhibition of mammary tumor development in *neu* transgenic mice 265-271

Bcl-2
increased in residual breast cancer following preoperative chemotherapy 107-116
benign breast cysts
ultrastructural characterization, biochemical profile, and hypothetical evolution 211-219
BRCA1 gene
LOH and exon 11 protein truncation analysis of mutations in familial and non-familial cases 259-264
bryostatin-1
antagonist/weak agonist of growth and prostaglandin production, via protein kinase C? 117-124

c-*erb*B-2
amplification in node-positive prognosis 21-32
CGS 20267
see letrozole
chemoresistance
see drug resistance
chromosome 8
heterogeneous aneuploidy by interphase FISH in all breast tumor specimens 125-133
clinical breast examination (CBE)
little effect on accuracy of radiologists' referral patterns 65-71
cyclin D1
overexpression does not protect from growth inhibition by sulindac 195-203
cyst fluid
classification — Na/K ratios, protein content, and hypothetical evolution 211-219
cystosarcoma phyllodes
see phyllodes tumor of the breast
cytogenetics
abnormalities in normal cells of sporadic breast cancer patients and first-degree relatives 187-190
cytogenetics, interphase
heterogeneous aneuploidy of chromosome 8 by interphase FISH in all breast tumor specimens 125-133

diagnosis
^{99m}Tc-Sestamibi scintimammography with a new high-resolution gamma camera 159-163
diet
weight management intervention in locoregional breast cancer 53-64
dominant-negative receptor variants
progesterone receptor splice variants found in breast cells 231-241
drug resistance
increase Bcl-2, decreased apoptosis and Ki67, in residual breast cancer following preoperative chemotherapy 107-116

endocrine therapy
letrozole, unlike aminoglutethimide, inhibits ovarian as well as tumor aromatase 45-51
endometrial cancer
endometrial thickening and possible cancer risk in women developing amenorrhea on tamoxifen 81-83

epidermal growth factor (EGF)
EGF receptor and EGF/TGFα activity in NMU rat mammary tumors 175-185
estrogen receptor
early changes after tamoxifen, vs. response 11-20
inhibition of DNA- and ligand-binding, and of transactivation, by polyamines 243-257
time-dependence of contribution to modified Nottingham Prognostic Index 1-9
estrogens
long-term conjugated equine — induce proliferation and PgR in macaque mammary glands 221-229
exercise
and weight management intervention in locoregional breast cancer 53-64

familial breast cancer
cytogenetic abnormalities in normal cells of sporadic breast cancer patients and first-degree relatives 187-190
LOH and exon 11 protein truncation analysis of *BRCA1* mutations 259-264
FISH (fluorescence in situ hybridization)
heterogeneous aneuploidy of chromosome 8 in all breast tumors 125-133

gamma camera
a new high-resolution gamma camera for ^{99m}Tc-Sestamibi scintimammography 159-163
ganglioside GM3
18 times higher in invasive MDA-MB-231 than in non-invasive MCF-7 cells 149-157
gene therapy
apoptosis in MCF-7 cells after infection with p53-carrying adenovirus 273-286
glycosphingolipids
composition in invasive MDA-MB-231 vs. non-invasive MCF-7 cells 149-157
gross cystic breast disease
ultrastructural characterization, biochemical profile, and hypothetical evolution 211-219

hormone dependence
presence of PgR splice variants and predictive accuracy of PgR measurements 231-241

hypoxia
correlation of percent hypoxic areas with intratumoral pO_2, size, and grade 97-106

immunotherapy
interferon-α treatment enhancement by conjugation with anti-breast-mucin antibody BrE-3 135-147
inositol triphosphates
induction by EGF/TGFα in NMU rat mammary tumors 175-185
interferon-α
treatment enhancement by conjugation with anti-breast-mucin antibody BrE-3 135-147
interleukin-1β
interaction with phorbol ester and bryostatin-1 in stimulating PGE_2 production 117-124
invasion
glycosphingolipid composition in invasive MDA-MB-231 vs. non-invasive MCF-7 cells 149-157

letrozole
inhibits ovarian as well as tumor aromatase, unlike aminoglutethimide 45-51
leukemia inhibitory factor (LIF)
and LIF receptor in ~80% of human breast cancers, correlated with favorable features 165-174
loss of heterozygosity
analysis of *BRCA1* mutations in familial and non-familial breast cancer 259-264
LOH on 16p, 16q, 17p, 17q, or 18q in node-positive breast cancer not prognostic 21-32

macaques, cynomolgus
effects of long-term estrogens, progestin, and tamoxifen on mammary glands 221-229
mammography
CBE reports have little effect on accuracy of radiologists' referral patterns 65-71
complemented by ^{99m}Tc-Sestamibi scintimammography with a new high-resolution gamma camera 159-163
markers
presence of PgR splice variants and predictive accuracy of PgR measurements 231-241

MCF-10F human breast epithelial cells
sulindac and metabolites: induction of $p21^{WAF1}$ and apoptosis 195-203
MCF-7 human breast cancer cells
apoptosis after infection with adenovirus carrying p53 273-286
glycosphingolipid composition vs. MDA-MB-231 cells 149-157
sulindac and metabolites: induction of apoptosis 195-203
MDA-MB-231 human breast cancer cells
effects of protein kinase C agonists on prostaglandin production and growth 117-124
glycosphingolipid composition vs. MCF-7 cells 149-157
medroxyprogesterone acetate
enhances long-term estrogen-induced proliferation of macaque mammary glands 221-229
menstrual cycle
no correlation with breast cancer proliferative rate (TLI) 93-94
micrometastasis
possible detection by interphase FISH of chromosome 8 125-133
MNU
see NMU
monoclonal antibodies
anti-breast-mucin antibody BrE-3 — interferon-α conjugate treatment in nude mouse model 135-147
morphometry
macaque mammary glandular proliferation by long-term estrogens, progestin, tamoxifen 221-229

neu transgenic mice
inhibition of mammary tumor development by retinoids 265-271
NMU-induced rat mammary tumors
decreased VDUP-1 (vitamin-D-regulated) after NMU precedes tumor appearance 33-44
EGF receptor and EGF/TGFα activity 175-185
Nottingham Prognostic Index
time-dependence of ER and PgR contributions to modified Index 1-9
NSAIDs (non-steroidal anti-inflammatory drugs)
sulindac and metabolites: induction of $p21^{WAF1}$ and apoptosis in breast and breast cancer cells 195-203

ovariectomy, medical
letrozole, unlike aminoglutethimide, inhibits ovarian as well as tumor aromatase 45-51
oxygen partial pressure
correlation with size, grade, percent hypoxic areas, in preoperative breast tumors 97-106

$p21^{WAF1}$
induction by sulindac and metabolites in breast and breast cancer cells 195-203
p53
apoptosis in MCF-7 cells after infection with p53-carrying adenovirus 273-286
importance of immunoreactivity over mutation in node-positive prognosis 21-32
phorbol esters
stimulation of growth and prostaglandin production; partial antagonism of bryostatin-1 117-124
phyllodes tumor of the breast
classification, extent of surgery, and outcome 205-210
polyamines
inhibition of estrogen receptor DNA- and ligand-binding 243-257
predictive factors
higher SRC-1 levels predict tamoxifen responsiveness 87-92
presence of PgR splice variants and predictive accuracy of PgR measurements for endocrine therapy 231-241
primates
effects of long-term estrogens, progestin, and tamoxifen on macaque mammary glands 221-229
progesterone receptor
early changes after tamoxifen, vs. response 11-20
induction by long-term conjugated estrogens or tamoxifen in macaque mammary glands 221-229
splice variants repress transcription by wild-type receptors 231-241

progesterone receptor (*cont.*)
time-dependence of contribution to modified Nottingham Prognostic Index 1-9
progestins
enhance long-term estrogen-induced proliferation of macaque mammary glands 221-229
prognostic factors
correlation with oxygen partial pressure (pO_2) and percent hypoxic areas 97-106
for phyllodes tumor of the breast 205-210
importance of c-*erb*B-2 and p53, not *int*-2 or LOH on 16p, 16q, 17p, 17q, or 18q in node-positive breast cancer 21-32
leukemia inhibitory factor (LIF) and LIF receptor in ~80% of human breast cancers, correlated with favorable features 165-174
PgR — possible confounding by presence of splice variants 231-241
time-dependence of ER and PgR contributions to modified Nottingham Index 1-9
proliferation markers
early changes in Ki67 after tamoxifen, vs. response 11-20
proliferative rate
parallels apoptosis; decreased following pre-operative chemotherapy 107-116
prostaglandins
PGE_2 production and arachidonate release stimulated by protein kinase C agonists TPA, bryostatin-1 117-124
prostate-specific antigen (PSA)
induction by norgestrel in T47D cells in SCID mice 73-80
protein kinase C
differential effects of agonists on prostaglandin production and growth 117-124
protein truncation test (PTT)
analysis of *BRCA1* mutations in familial and non-familial breast cancer 259-264
psychological status
and weight management intervention in loco-regional breast cancer 53-64

retinoids
inhibition of mammary tumor development in *neu* transgenic mice by 4-HPR, arotinoid Ro 40-8757 265-271

scintigraphy
^{99m}Tc-Sestamibi scintimammography with a new high-resolution gamma camera 159-163
screening
CBE reports have little effect on accuracy of radiologists' referral patterns 65-71
spermine
inhibits estrogen receptor ligand-binding 243-257
sporadic breast cancer
LOH and exon 11 protein truncation analysis of *BRCA1* mutations 259-264
SRC-1 steroid receptor coactivator
higher levels predict tamoxifen responsiveness 87-92
sulindac
and metabolites: induction of $p21^{WAF1}$ and apoptosis in breast and breast cancer cells 195-203
surgery
for phyllodes tumor of the breast — extent, prognostic factors, and outcome 205-210
menstrual timing — no correlation with breast cancer proliferative rate (TLI) 93-94

T47-D human breast cancer cells
PSA induction by norgestrel in SCID mice 73-80
tamoxifen
early changes in hormone receptors and proliferation markers, vs. response 11-20
endometrial thickening and possible cancer risk in women developing amenorrhea 81-83
response correlates with higher levels of receptor coactivator SRC-1 87-92
transcription factors
polyamine inhibition of estrogen receptor DNA- and ligand-binding and transactivation 243-257

vitamin-D-regulated gene VDUP-1
decreases in mammary gland after NMU, before tumor appearance 33-44

weight management
intervention program in locoregional breast cancer patients 53-64